All In Biotech

Drug Trial Radar · NCT03439670

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 19, 2026Latest source record: Mar 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

121

Actual

Start

Jun 29, 2018

Primary completion

Feb 23, 2021

Study completion Aug 19, 2021

Sponsor

Lead sponsor
ReveraGen BioPharma, Inc.Industry
Sponsor type
Industry
Collaborators
European Union; Cooperative International Neuromuscular Research Group; Newcastle University; University of Pittsburgh
First posted
Feb 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Brief Summary: This Phase IIb study is a randomized, double-blind, parallel group, placebo and active-controlled study to evaluate the efficacy, safety, PD, and population PK of vamorolone administered orally at daily doses of 2.0 mg/kg and 6.0 mg/kg versus prednisone 0.75 mg/kg/day and placebo over a Treatment Period of 24 weeks, and to evaluate persistence of effect over a Treatment Period of 48 weeks in ambulant boys ages 4 to \<7 years with DMD.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • VamoroloneDrug

    Oral administration of 2.0 mg/kg/day for the duration of the study.

  • PrednisoneDrug

    Oral administration of 0.75 mg/kg/day for 24 weeks.

  • PlaceboOther

    Oral administration of placebo daily for 24 weeks.

  • VamoroloneDrug

    Oral administration of 6.0 mg/kg/day for the duration of the study.

  • PrednisoneDrug

    Oral administration of 0.75 mg/kg/day for 24 weeks.

  • PlaceboOther

    Oral administration of placebo daily for 24 weeks.

  • VamoroloneDrug

    Oral administration of 2.0 mg/kg/day for 20 weeks.

  • VamoroloneDrug

    Oral administration of 6.0 mg/kg/day for 20 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Measured by Time to Stand Test (TTSTAND) Velocity in Rises/Second Change From BaselineTime frame: 24 weeks

Locations

33 sites in 11 countries. Site status is shown where the registry gives one.

  • University of California Davis

    Davis, California

  • University of California Los Angeles

    Los Angeles, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nemours Children's Hospital

    Orlando, Florida

  • Ann & Robert H. Lurie Children's Hospital

    Chicago, Illinois

  • Gillette Children's Speciality Health Care

    Saint Paul, Minnesota

  • Duke Children's Hospital

    Durham, North Carolina

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Children's Hospital of Virginia of Virginia Commonwealth University

    Richmond, Virginia

  • Seattle Children's Hospital

    Seattle, Washington

  • Royal Children's Hospital

    Melbourne, Australia

  • Sydney Children's Hospital

    Westmead, Australia

  • Ghent University Hospital

    Ghent, Belgium

  • University Hospitals Leuven

    Leuven, Belgium

  • Alberta's Children Hospital

    Calgary, Alberta, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, Canada

  • Montreal Children's Hospital

    Montreal, Quebec, Canada

  • University Hospital Brno

    Brno, Czechia

  • Charles University

    Prague, Czechia

  • Agia Sofia Children's Hospital

    Athens, Greece

  • Schneider Children's Medical Center

    Petah Tikvah, Israel

  • Leiden University Medical Center

    Leiden, Netherlands

  • Radboud University

    Nijmegen, Netherlands

  • Sant Joan de Deu Hospital - Barcelona, Spain

    Barcelona, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • Queen Silvia Children's Hospital

    Gothenburg, Sweden

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom

  • Royal Hospital for Children

    Glasgow, United Kingdom

  • Leeds Teaching Hospital Trust

    Leeds, United Kingdom

  • Alder Hey Children's NHS Foundation Trust

    Liverpool, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

  • Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.